LEADER 02312nam  2200517 a 450 
001 9910790451003321
005 20230801221556.0
010   $a1-60805-297-4
035   $a(CKB)2670000000148694
035   $a(EBL)864207
035   $a(OCoLC)779141401
035   $a(SSID)ssj0000942934
035   $a(PQKBManifestationID)11492225
035   $a(PQKBTitleCode)TC0000942934
035   $a(PQKBWorkID)10976890
035   $a(PQKB)11670260
035   $a(OCoLC)785783102
035   $a(MiAaPQ)EBC864207
035   $a(EXLCZ)992670000000148694
100   $a20120315d2012      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aMultiple myeloma$b[electronic resource] $ea new era of treatment strategies /$feditors, Klaus Podar, Kenneth C. Anderson
210   $a[U.S.A.] $cBentham Science Publishers$d[2012]
215   $a1 online resource (217 p.)
300   $aDescription based upon print version of record.
311   $a1-60805-609-0 
320   $aIncludes bibliographical references and index.
327   $asection 1. Multiple myeloma -- section 2. Treatment guidelines -- section 3. The bone marrow microenvironment and the pathogenesis of multiple myeloma -- section 4. New treatment strategies.
330   $aMultiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell
606   $aMultiple myeloma$xTreatment
615  0$aMultiple myeloma$xTreatment.
676   $a616.99/418
676   $a616.99418
701   $aPodar$b Klaus$01522445
701   $aAnderson$b Kenneth C$0876632
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910790451003321
996   $aMultiple myeloma$93762155
997   $aUNINA